Organization
TN
12 abstracts
Abstract
Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.Org: Department of Urologic Sciences, Vancouver General Hospital, Canada, BC Cancer - Vancouver Centre, BC,
Abstract
Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.Org: Copenhagen University Hospital, Washington University School of Medicine, ModernaTX, Rigshospitalet, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit,
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO).Org: Nashville, OneOncology, TN, South San Francisco, Genentech,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS).Org: Tennessee Oncology, PLLC, Chattanooga, TN, Nashville, West Cancer Center & Research Institute,
Abstract
Biomarker-driven prospective clinical trial in renal cell carcinoma: Developing machine learning models to allocate patients to treatment arms using RNA sequencing.Org: Vindhya Data Science, Durham Veteran Affairs Medical Center, NC Medical Research, Vanderbilt University Medical Center, Nashville,
Abstract
Pathway enrichment analysis in tumors with high mutation burdens and interferon-γ signature expression: A pancancer analysis.Org: Vanderbilt University Medical Center, Nashville, TN,
Abstract
Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.Org: Medical College of Wisconsin, Milwaukee, WI, Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland, IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli” and Dipartimento di Medicina Specialistica,
Abstract
Rates of routine cancer screening compared with pre-pandemic levels.Org: Trilliant Health, Brentwood, TN, TN,